Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully transition investigational drugs from research to a commercially profitable product. These companies need to secure a combination of sophisticated investors, partners, and expert consultants to reach their goals.
Venture capital investors, in-licensing parties, and partner deal makers use the asset evaluation/due diligence process to assess a drug program’s risk, risk mitigation, and probability of success. Watch this short video by Dr. Fran Brown, Senior Vice President at Certara, to learn about 7 issues that were the “kiss of death” for investors considering drug development programs!
About Our Speaker
Dr. Fran Brown is currently the SVP of Drug Development Services in Certara’s Integrated Drug Development Division. She is a highly respected professional with proven leadership skills and 25 years of broad experience within pharmaceutical development and due diligence/asset evaluation. Fran possesses a broad knowledge of strategic drug discovery and development, with a special focus on development strategy and the application of Model Informed Drug Development.